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Sirs,
For a patient who presents with isolated microscopic
hematuria, three different disease entities that enter the
differential diagnosis are: (a) immunoglobulin A (IgA)
nephropathy, with no family history, that may also express
itself with macroscopic hematuria; (b) Alport syndrome,
which may present with episodes of macroscopic hematuria
during childhood and should most frequently be explained
by a family history of chronic kidney disease (most
frequently X-linked, 85% and, less frequently, of autosomal
recessive inheritance); (c) thin basement membrane ne-
phropathy (TBMN), which invariably leads to benign
familial microscopic hematuria (BFMH), with family
history and infrequent episodes of macroscopic hematuria,
while it is normally not expected to be accompanied by
severe kidney disease, apart from low-grade proteinuria.
TBMN as a heritable condition has been attributed to
heterozygous mutations in the collagen type IV, alpha 3 and
alpha 4 (COL4A3/COL4A4) genes on chromosome 2q36–
37, by nearly 50%. It should not be a surprise if closer look
and improved techniques prove that COL4A3/COL4A4
mutations account for an even higher portion of TBMN
cases that presently have been overlooked. The term
TBMN, with only few exceptions, has largely been used
as a synonym for benign familial microscopic hematuria,
which nearly always is the only symptom, with excellent
prognosis [1–3]. Those few exceptions are worth concen-
trating on, in view of a recent publication from my
laboratory, which provides voluminous exceptional data
from a population on the island of Cyprus [4]. In that report
we described 13 families with the dual diagnosis of TBMN
and focal segmental glomerulosclerosis (FSGS), while, in
ten of them, we identified three heterozygous mutations in
the COL4A3/COL4A4 genes. Combination of that data with
more recent work concludes that, in a total of 59 patients
over the age of 51 years, approximately two in three had
developed proteinuria and chronic kidney disease, while
about one in three had progressed to end-stage kidney
disease (ESKD), as evidenced by the need for hemodialysis
or kidney transplantation [4, 5 and unpublished results].
Older publications had attested to similar exceptions as
regards the prognosis of TBMN, reporting on relatively
small numbers of patients, a few of whom had presented
also with additional glomerular pathologies that included
proteinuria, FSGS and chronic kidney disease, occasionally
also ESKD. As early as 1985, Dische et al. [6] reported on
14 TBMN patients aged 11–51 years, several of whom had
progressive disease including hypertension and renal
impairment, while one had reached ESKD. Nieuwhof et
al. [7], in a prospective 12-year follow-up study of 19
patients with TBMN and microscopic (18/19) or macro-
scopic hematuria (1/19), were the first to clearly associate
TBMN with late-onset renal impairment in elderly patients.
In 13.5% of their patients focal global glomerulosclerosis
was detected, while six first-degree relatives reached
ESΚD, prompting the authors to conclude that TBMN
predisposes to premature glomerular obsolescence, which,
with sufficient time, leads to increased incidence of
hypertension and late-onset renal insufficiency. Interesting-
ly, the same authors mentioned that in a separate series of
TBMN patients they had noted an increased proteinuria
associated with FSGS in the renal biopsy. Based on their
admittedly small patient cohort the authors commented that
the prognosis of TBMN may not be as benign as generally
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thought. Subsequent reports described similar findings
where, occasionally, TBMN patients did not follow a benign
course but, rather, they progressed to FSGS and proteinuria
or hypertension that developed into chronic kidney disease
or ESKD, thereby prompting the authors to allude to other
co-inherited glomerulopathies or to the notion that TBMN
predisposes to renal impairment [8, 9]. Obviously, often-
times, TBMN can be a benign disease; however, in the
presence of additional symptoms such as proteinuria or a
family history of kidney failure, a renal biopsy is clearly
warranted in addition to close follow up [10, 11].
In view of the above findings and the findings by
Voskarides et al. [4], it was tempting to hypothesize that
TBMN is not always a benign condition but rather a
situation which predisposes COL4A3/COL4A4 heterozy-
gous carriers to a higher risk for proteinuria or FSGS and
renal failure, when another genetic modifier is co-inherited.
In a recent publication in this journal Tonna et al. [12]
reported on 56 TBMN patients (on the basis of persistent
hematuria), some of whom also had proteinuria of
≥300 mg/l, or ≥500 mg/l. Among these, 3 of 5 (60%)
who carried the R229Q variant of the glomerular filtration
barrier protein podocin [encoded by the nephrosis 2
(NPHS2) gene] had proteinuria of ≥500 mg/l, whereas only
7 of 51 (14%) who did not carry R229Q had a similar level
of proteinuria. This showed statistical significance, al-
though the numbers are somewhat small, clearly needing
confirmation by independent larger studies. This implies
that TBMN patients who are also heterozygous carriers of
the R229Q variant in podocin are predisposed to a
somewhat more severe phenotype. However, in the same
cohort, none of nine patients with TBMN and coincidental
glomerular or tubulointerstitial disease carried R229Q,
thereby not supporting the notion of a confounding
negative role. Also, from work in my laboratory, none of
43 patients over 45 years of age with TBMN and a proven
COL4A3/COL4A4 mutation and documented proteinuria or
chronic kidney disease carried this podocin variant (unpub-
lished results). This variant has a frequency of 4% in the
general Cypriot population. It is worth mentioning that,
although an earlier report had associated R229Q with
microalbuminuria in the Brazilian population, a more recent
work with larger numbers did not corroborate those data in
a US adult population [13, 14].
In conclusion, the implication that variant R229Q in the
podocin protein may predispose to proteinuria in TBMN
[12] is somewhat premature and needs further experimen-
tation. It is equally important either to confirm this
association or to reject it; however, it is of paramount
importance for us to identify the factor or factors that
clearly predispose a subgroup of TBMN patients to
proteinuria, or even FSGS and renal failure, thereby
enabling us to identify high-risk patients for early interven-
tion. Apparently, founder phenomena and geographic
clustering may have contributed to the unusual findings in
the Cypriot population where a high proportion of
COL4A3/COL4A4 carriers proceed to FSGS and renal
failure [4, 5].
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